軽度認知障害の世界市場

軽度認知障害の世界市場は2030年までに26億米ドルに到達

2024年に20億米ドルと推定される軽度認知障害の世界市場は、分析期間2024-2030年にCAGR 4.3％で成長し、2030年には26億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである健忘性軽度認知症疾患は、CAGR 3.4%を記録し、分析期間終了時には15億米ドルに達すると予測されます。軽度認知症疾患セグメントの成長率は、分析期間中CAGR 5.6%と推定されます。

米国市場は5億4,360万米ドルと推定、中国はCAGR 7.6％で成長予測

米国の軽度認知障害市場は、2024年に5億4,360万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 7.6%で推移し、2030年には5億2,110万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.8％と3.3％と予測されています。欧州では、ドイツがCAGR 2.5%で成長すると予測されています。

世界の軽度認知障害市場- 主要動向と促進要因のまとめ

神経医療において軽度認知障害はどのように重要な焦点になりつつあるのか？

軽度認知障害（MCI）は、正常な老化と認知症やアルツハイマー病に伴うより深刻な衰えの間に存在する重要な神経学的状態として、ますます認識されるようになっています。MCIは、記憶、思考、または推論の顕著な変化を特徴とし、それは個人の年齢から予想されるよりも大きいが、日常生活に大きな支障をきたすほど深刻ではないです。世界人口の急速な高齢化に伴い、MCIは、より衰弱性の高い神経変性疾患に進展する可能性があるため、公衆衛生上の優先事項として注目されています。早期の認知機能低下に対する認識が高まり、ヘルスケア提供者はスクリーニングと早期診断をより重視するようになりました。また、患者や家族も、物忘れ、集中困難、言葉が見つからないなどの初期徴候に敏感になっており、より多くの臨床診察や評価を受けるようになっています。MCIが明確な診断カテゴリーとして登場したことで、神経科医はより重篤な疾患の発症を遅らせたり、予防したりする介入戦略を模索するようになりました。さらに、身体活動、認知活動、睡眠衛生、食事などの生活習慣がMCIの進行に影響する可能性があることが調査から示されており、患者のケアに学際的な関与が必要とされています。認知リハビリテーションプログラムやデジタル認知トレーニングツールは、早期の機能低下をターゲットとし、機能を維持するために開発されています。MCIが必ずしも認知症につながるとは限らないが、MCIが発見されれば、介入、モニタリング、支援のための重要な機会が得られます。早期の認知機能変化に対する臨床的・社会的な注目の高まりは、MCIをより広範な認知・神経健康分野における重要な研究分野へと変貌させつつあります。

なぜ早期発見と診断がMCI研究と治療の革新を推進するのか？

早期発見と診断は、診断技術、リスク評価、臨床経路の革新を促し、軽度認知障害を管理する取り組みの中心となっています。MCIを早期に発見することは、認知機能低下を遅らせたり、安定させたりする介入を実施するための重要な時間を提供することができます。ヘルスケアシステムでは、モントリオール認知機能評価（MoCA）やミニメンタルステート検査（MMSE）などの標準化された認知機能評価や、リアルタイムの認知機能モニタリングや遠隔検査機能を提供する新しいデジタルツールの導入が進んでいます。バイオマーカー研究も急速に進んでおり、神経画像、脳脊髄液分析、血液ベースの検査が、MCIと正常な老化や初期のアルツハイマー病病理との鑑別のために研究されています。人工知能や機械学習モデルは、患者データを解析し、認知症への進行の可能性を予測するために開発されており、臨床医に強力な新しい意思決定手段を提供しています。遺伝子検査と個別化医療のアプローチは、特に認知障害の家族歴やAPOE4遺伝子の変異体などの既知の危険因子を有する患者において、リスクプロファイリングをさらに精緻化しています。これらの進歩は、早期発見を助けるだけでなく、より正確で的を絞った治療介入の開発を形成しています。製薬企業がMCIにおける認知機能低下の遅延や阻止に焦点を当てた臨床試験に投資する中、診断技術の革新は、適格な患者を特定し、治療成果を追跡する上で不可欠なものとなりつつあります。さらに、早期診断により、積極的な生活設計、併存疾患のより良い管理、支援サービスの利用が可能になり、患者や介護者に力を与えることができます。世界の医療機関が早期認知ヘルスをエイジングケアの礎石として強調する中、早期発見の推進はMCIの研究課題とヘルスケア提供モデルの両方を再構築しつつあります。

生活習慣への介入と非薬理学的戦略はMCI管理にどのような影響を与えているか？

非薬理学的戦略や生活習慣への介入は、認知機能低下を遅らせる有効性を支持するエビデンスの増加により、MCI管理においてますます重要な役割を果たしています。現在、MCIに特化してFDAが承認した薬剤はないが、身体活動、認知刺激、社会参加、栄養をターゲットとした構造化された介入が、認知パフォーマンスと全体的なQOLに有意な利益をもたらすことが調査で示されています。ウォーキング、サイクリング、筋力トレーニングなどの有酸素運動は、脳血流を促進し、神経可塑性を促進することにより、実行機能と記憶力の改善に関連しています。認知トレーニングプログラムは、対面式でもデジタル式でも、注意力、処理速度、言葉の流暢さといった特定の認知領域を強化するのに役立っています。さらに、果物、野菜、全粒穀物、健康的な脂肪、赤身のタンパク質を重視する地中海食やMIND食などの食事パターンが、神経保護効果の可能性について研究されています。マインドフルネスの実践、瞑想、十分な睡眠衛生も、ストレスの軽減と認知機能の維持に有望です。地域社会に根ざしたプログラムや集団介入は、社会的なつながりを育むものであり、認知機能の低下を予防するものとして認識されつつあります。ヘルスケアプロバイダーは、これらのライフスタイル戦略を取り入れた個別のケアプランを開発しており、一貫性と関与を強化するために介護者や家族も関与しています。公衆衛生の取り組みや啓発キャンペーンは、特に高齢者集団の間で、より広範な認知健康戦略の一環としてこれらの介入を推進しています。全人的で患者中心の管理へのこのシフトは、MCIが行動的、環境的、遺伝的要因に影響される多因子疾患であるという深い理解を反映したものであり、認知老化におけるライフスタイルの重要な役割を浮き彫りにしています。

軽度認知障害への世界の注目の高まりの主な要因は何か？

軽度認知障害への世界の注目の高まりは、人口統計学的、臨床的、社会的、技術的要因の合流によってもたらされています。その最たるものが世界人口の高齢化であり、MCIを含む加齢に伴う認知障害の急増につながっています。長寿化とともに認知機能低下の有病率も増加し、MCIは認知症やアルツハイマー病への進展を防ぐための早期介入の重要な標的となっています。一般市民の意識向上キャンペーンや教育イニシアティブは、認知機能の変化に対する認識を向上させ、ヘルスケアへの早期関与と診断を促しています。同時に、神経科学と診断学の進歩により、認知機能障害をより正確に同定し、層別化することが可能になり、時宜を得た適切な介入を行う機会が生まれています。医療制度や政府が早期発見・早期治療に投資することで、長期的な治療費を削減しようとしているためです。製薬会社やバイオテクノロジー企業も、MCIを臨床イノベーションの重要な入口と位置づけ、早期認知機能低下の治療法開発を目指した研究努力を強化しています。さらに、デジタルヘルス技術の普及は、継続的な認知評価や遠隔患者モニタリングをサポートし、認知ケアをより身近でスケーラブルなものにしています。政策立案者や保険会社は、早期介入プログラムの長期的価値を認識しており、認知医療サービスに対する償還政策や資金援助につながっています。こうした複合的な要因が、MCIに焦点を当てた世界のイニシアチブの背後に強い勢いを生み出しており、MCIは高齢化と脳の健康という広範な文脈における課題であると同時に機会でもあると位置付けられています。MCIに対する理解が進むにつれて、個人レベルでもシステムレベルでも、MCIに対処するための取り組みの緊急性と協調性が高まっています。

セグメント

疾患（健忘性軽度認知症、軽度認知症）、適応症（レビー小体型認知症、パーキンソン病、アルツハイマー病、血管性認知症、その他の適応症）、治療（薬物、療法）

調査対象企業の例

• AbbVie Inc.
• AC Immune SA
• Alzheon, Inc.
• Alector, Inc.
• Anavex Life Sciences Corp.
• Biogen Inc.
• Cassava Sciences, Inc.
• Cognivue, Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Genentech（Roche Group）
• Huron Digital Pathology
• Johnson & Johnson
• Karuna Therapeutics
• MedRhythms, Inc.
• Neurotrack Technologies, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Roche Holding AG
• Sage Therapeutics, Inc.
• Takeda Pharmaceutical Company

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Mild Cognitive Impairment Market to Reach US$2.6 Billion by 2030

The global market for Mild Cognitive Impairment estimated at US$2.0 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Amnestic Disease, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Non-Amnestic Disease segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$543.6 Million While China is Forecast to Grow at 7.6% CAGR

The Mild Cognitive Impairment market in the U.S. is estimated at US$543.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$521.1 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Mild Cognitive Impairment Market - Key Trends & Drivers Summarized

How Is Mild Cognitive Impairment Emerging as a Critical Focus in Neurological Health?

Mild Cognitive Impairment (MCI) is increasingly recognized as a significant neurological condition that exists between normal aging and the more severe decline associated with dementia and Alzheimer’s disease. It is characterized by noticeable changes in memory, thinking, or reasoning that are greater than expected for an individual’s age but not severe enough to interfere significantly with daily activities. With the global population aging rapidly, MCI has gained prominence as a public health priority due to its potential to progress into more debilitating neurodegenerative diseases. The rising awareness of early cognitive decline has prompted healthcare providers to place greater emphasis on screening and early diagnosis. Patients and families are also becoming more attuned to the early signs, such as forgetfulness, difficulty concentrating, and trouble finding words, leading to more clinical consultations and evaluations. MCI’s emergence as a distinct diagnostic category has encouraged neurologists to explore intervention strategies that could slow or prevent the onset of more serious conditions. Furthermore, research indicates that lifestyle factors such as physical activity, cognitive engagement, sleep hygiene, and diet may influence the progression of MCI, prompting broader interdisciplinary involvement in patient care. Cognitive rehabilitation programs and digital cognitive training tools are being developed to target early-stage decline and preserve function. While MCI does not always lead to dementia, its identification provides a critical window of opportunity for intervention, monitoring, and support. This growing clinical and societal focus on early cognitive changes is transforming MCI into a key area of study within the broader field of cognitive and neurological health.

Why Is Early Detection and Diagnosis Driving Innovation in MCI Research and Treatment?

Early detection and diagnosis are becoming central to efforts in managing Mild Cognitive Impairment, prompting innovation in diagnostic technologies, risk assessments, and clinical pathways. Recognizing MCI at an early stage can provide critical time for implementing interventions that may slow or stabilize cognitive decline. Healthcare systems are increasingly adopting standardized cognitive assessments such as the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), as well as new digital tools that offer real-time cognitive monitoring and remote testing capabilities. Biomarker research is also advancing rapidly, with neuroimaging, cerebrospinal fluid analysis, and blood-based tests being explored to differentiate MCI from normal aging and early Alzheimer’s pathology. Artificial intelligence and machine learning models are being developed to analyze patient data and predict the likelihood of progression to dementia, offering clinicians powerful new decision-making tools. Genetic testing and personalized medicine approaches are further refining risk profiling, particularly in patients with a family history of cognitive disorders or known risk factors such as APOE4 gene variants. These advancements are not only aiding early detection but are also shaping the development of more precise and targeted therapeutic interventions. As pharmaceutical companies invest in clinical trials focused on delaying or halting cognitive decline in MCI, diagnostic innovation is becoming indispensable in identifying eligible patients and tracking therapeutic outcomes. Moreover, early diagnosis empowers patients and caregivers by enabling proactive life planning, better management of comorbidities, and access to supportive services. With global health organizations emphasizing early cognitive health as a cornerstone of aging care, the drive for early detection is reshaping both the research agenda and the healthcare delivery model for MCI.

How Are Lifestyle Interventions and Non-Pharmacological Strategies Impacting MCI Management?

Non-pharmacological strategies and lifestyle interventions are playing an increasingly important role in the management of Mild Cognitive Impairment, driven by a growing body of evidence that supports their efficacy in slowing cognitive decline. While there is currently no FDA-approved medication specifically for MCI, research has shown that structured interventions targeting physical activity, cognitive stimulation, social engagement, and nutrition can significantly benefit cognitive performance and overall quality of life. Aerobic exercises such as walking, cycling, and strength training have been linked to improved executive function and memory by enhancing cerebral blood flow and promoting neuroplasticity. Cognitive training programs, both in-person and digital, are helping patients strengthen specific cognitive domains such as attention, processing speed, and verbal fluency. Additionally, dietary patterns such as the Mediterranean and MIND diets, which emphasize fruits, vegetables, whole grains, healthy fats, and lean proteins, are being studied for their potential neuroprotective effects. Mindfulness practices, meditation, and adequate sleep hygiene are also showing promise in reducing stress and preserving cognitive function. Community-based programs and group interventions are fostering social connectivity, which is increasingly recognized as protective against cognitive deterioration. Healthcare providers are developing personalized care plans that incorporate these lifestyle strategies, often involving caregivers and family members to reinforce consistency and engagement. Public health initiatives and awareness campaigns are promoting these interventions as part of broader cognitive health strategies, particularly among aging populations. This shift toward holistic, patient-centered management reflects a deeper understanding of MCI as a multifactorial condition influenced by behavioral, environmental, and genetic factors, and highlights the critical role of lifestyle in cognitive aging.

What Are the Main Drivers Behind the Rising Global Focus on Mild Cognitive Impairment?

The growth in global focus on Mild Cognitive Impairment is being driven by a confluence of demographic, clinical, societal, and technological factors. Foremost among these is the aging global population, which is leading to a sharp rise in age-related cognitive disorders, including MCI. As longevity increases, so does the prevalence of cognitive decline, making MCI a critical target for early intervention to prevent the escalation to dementia and Alzheimer’s disease. Public awareness campaigns and education initiatives are improving recognition of cognitive changes, encouraging earlier healthcare engagement and diagnosis. At the same time, advances in neuroscience and diagnostics are enabling more accurate identification and stratification of cognitive impairment, creating opportunities for timely and tailored interventions. The economic impact of dementia-related illnesses is another significant driver, as health systems and governments seek to reduce the long-term costs of care by investing in early-stage detection and treatment. Pharmaceutical and biotechnology companies are also intensifying research efforts aimed at developing therapies for early cognitive decline, viewing MCI as a key entry point for clinical innovation. Additionally, the proliferation of digital health technologies is supporting continuous cognitive assessment and remote patient monitoring, making cognitive care more accessible and scalable. Policymakers and insurers are recognizing the long-term value of early intervention programs, leading to supportive reimbursement policies and funding for cognitive health services. These combined factors are creating a strong momentum behind global initiatives focused on MCI, positioning it as both a challenge and an opportunity in the broader context of aging and brain health. As the understanding of MCI evolves, so does the urgency and coordination of efforts to address it at both individual and systemic levels.

SCOPE OF STUDY:

The report analyzes the Mild Cognitive Impairment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease (Amnestic Disease, Non-Amnestic Disease); Indication (Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication, Other Indications); Treatment (Medication Treatment, Therapy Treatment)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• AbbVie Inc.
• AC Immune SA
• Alzheon, Inc.
• Alector, Inc.
• Anavex Life Sciences Corp.
• Biogen Inc.
• Cassava Sciences, Inc.
• Cognivue, Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Genentech (Roche Group)
• Huron Digital Pathology
• Johnson & Johnson
• Karuna Therapeutics
• MedRhythms, Inc.
• Neurotrack Technologies, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Roche Holding AG
• Sage Therapeutics, Inc.
• Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Mild Cognitive Impairment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Aging Population Worldwide Throws the Spotlight on Mild Cognitive Impairment as a Public Health Priority
  • Growing Awareness and Early Diagnosis Campaigns Propel Demand for MCI Screening and Monitoring Tools
  • Advancements in Neuroimaging and Biomarker Development Strengthen the Business Case for Precision MCI Diagnostics
  • Shift Toward Preventive Neurology Expands the Addressable Market for Early-Stage Cognitive Therapeutics
  • Integration of Digital Health Platforms and Cognitive Assessment Apps Drives Adoption of At-Home Monitoring for MCI
  • Link Between Cardiovascular Health and Cognitive Decline Spurs Multi-Disciplinary Approaches in MCI Management
  • Rising Incidence of Lifestyle-Linked Cognitive Disorders Sustains Growth in Non-Pharmacological Interventions
  • Push for FDA Approval of Disease-Modifying Therapies Throws the Spotlight on the MCI Pipeline in Alzheimer's Spectrum
  • Adoption of AI and Machine Learning in Cognitive Analytics Drives Innovation in Early Detection Algorithms
  • Stigma Reduction and Mental Health Awareness Generate Opportunities for Community-Based MCI Support Programs
  • Challenges in Differentiating MCI from Normal Aging Highlight the Need for Standardized Diagnostic Criteria
  • Use of Wearables and Remote Patient Monitoring Tools Expands Real-Time Tracking of Cognitive Function in MCI Patients
  • Growing Employer and Insurer Interest in Cognitive Health Drives Corporate Wellness Integration of MCI Screening
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Mild Cognitive Impairment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Mild Cognitive Impairment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Amnestic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Amnestic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Amnestic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Non-Amnestic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Non-Amnestic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Non-Amnestic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Lewy Body Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Lewy Body Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Lewy Body Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Parkinson's Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Parkinson's Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Parkinson's Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Alzheimer's Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Alzheimer's Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Alzheimer's Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Vascular Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Vascular Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Vascular Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Medication Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• JAPAN
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• CHINA
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: China 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• EUROPE
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Mild Cognitive Impairment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• FRANCE
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: France 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• GERMANY
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: Spain 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Russia 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Mild Cognitive Impairment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Australia 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• INDIA
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: India 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: South Korea 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Mild Cognitive Impairment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Latin America 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Argentina 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Brazil 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Mexico 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Mild Cognitive Impairment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: Middle East 16-Year Perspective for Mild Cognitive Impairment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Iran 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Israel 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: UAE 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
• AFRICA
  • Mild Cognitive Impairment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Mild Cognitive Impairment by Disease - Amnestic Disease and Non-Amnestic Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Africa 16-Year Perspective for Mild Cognitive Impairment by Disease - Percentage Breakdown of Value Sales for Amnestic Disease and Non-Amnestic Disease for the Years 2014, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Mild Cognitive Impairment by Indication - Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Mild Cognitive Impairment by Indication - Percentage Breakdown of Value Sales for Lewy Body Dementia Indication, Parkinson's Indication, Alzheimer's Indication, Vascular Dementia Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Mild Cognitive Impairment by Treatment - Medication Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Mild Cognitive Impairment by Treatment - Percentage Breakdown of Value Sales for Medication Treatment and Therapy Treatment for the Years 2014, 2025 & 2030

IV. COMPETITION